Aspire Biopharma Holdings, Inc.(ASBPW)Earnings, Financials & Key Ratios
ASBPW•NASDAQ
$0.02
$146747 mkt cap·Price updated May 6, 2026
AboutAspire Biopharma Holdings, Inc. is a biotechnology company specializing in advanced diagnostic solutions and molecular testing. The company focuses on developing high-precision assays for disease detection, leveraging cutting-edge research in genetics and biochemistry to support healthcare and life sciences industries.Show more
- Revenue$0
- EBITDA-$12M-360.4%
- Net Income-$13M-380.8%
- EPS (Diluted)-1.52-381.5%
- Interest Coverage-3.46+97.7%
ASBPW Key Insights
Aspire Biopharma Holdings, Inc. (ASBPW) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Weak momentum: RS Rating 7 (bottom 7%)
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
ASBPW Price & Volume
Aspire Biopharma Holdings, Inc. (ASBPW) stock price & volume — 10-year historical chart
Loading chart...
ASBPW Growth Metrics
Aspire Biopharma Holdings, Inc. (ASBPW) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-6467.87%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1740.89%
Return on Capital
10 Years-
5 Years-
3 Years-
Last Year-
ASBPW Peer Comparison
Aspire Biopharma Holdings, Inc. (ASBPW) competitors in Diagnostics and Omics Tools — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SNDL | 373.25M | 1.44 | -32.61 | 2.82% | -1.17% | -1% | 0.15 | |
 GRWG | 81.98M | 1.37 | -3.43 | -14.36% | -14.87% | -22.9% | 0.30 | |
 IIPR | 1.65B | 57.69 | 14.68 | -13.8% | 45.58% | 6.41% | 0.21 | |
 ACB | 200.75M | 3.54 | 168.77 | 27.01% | 11.24% | 7.15% | 0.17 | |
 HYFM | 5.32M | 1.14 | -0.08 | -16.02% | -44.49% | -32.29% | 0.76 | |
 LWAY | 405.93M | 26.65 | 29.94 | 13.74% | 6.52% | 17.25% | 0.00 | |
 SGBX | 32.96K | 0.96 | -0.00 | -69.88% | -5.69% | -77.2% | ||
 ATAI | 1B | 4.17 | -4.48 | -1.91% | -51.09% | -96.43% | 0.21 |
Compare ASBPW vs Peers
Aspire Biopharma Holdings, Inc. (ASBPW) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ASBPW Income Statement
Aspire Biopharma Holdings, Inc. (ASBPW) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 1.94K |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 1.06K |
| COGS % of Revenue | - | - | - | - |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 884▲ 0% |
| Gross Margin % | - | - | - | 45.54% |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 976.35K | 1.34M | 3.09M | 20.02M |
| OpEx % of Revenue | - | - | - | - |
| Selling, General & Admin | 421.18K | 1.34M | 3.09M | 19.22M |
| SG&A % of Revenue | - | - | - | - |
| Research & Development | 175.32K | 72.05K | 0 | 823.88K |
| R&D % of Revenue | - | - | - | - |
| Other Operating Expenses | 379.85K | -72.05K | 0 | -28.09K |
| Operating Income | -976.35K▲ 0% | -1.34M▼ 37.3% | -3.09M▼ 130.5% | -20.02M▲ 0% |
| Operating Margin % | - | - | - | -1031395.52% |
| Operating Income Growth % | - | -37.26% | -130.47% | - |
| EBITDA | -596K | 4.47M | -11.65M | -28.18M |
| EBITDA Margin % | - | - | - | -1451798.04% |
| EBITDA Growth % | - | 850.5% | -360.36% | -5749.24% |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 1.15M |
| EBIT | -596K | 4.47M | -11.65M | -29.32M |
| Net Interest Income | 4.32M | 5.8M | -343K | -2.72M |
| Interest Income | 4.32M | 5.81M | 548.68K | 67.17K |
| Interest Expense | 0 | 8.97K | 891.62K | 2.79M |
| Other Income/Expense | 379.97K | 5.8M | -9.45M | -11.72M |
| Pretax Income | -596.37K▲ 0% | 4.46M▲ 848.5% | -12.54M▼ 380.8% | -31.74M▲ 0% |
| Pretax Margin % | - | - | - | -1635228.54% |
| Income Tax | 626 | 0 | 0 | -1.01K |
| Effective Tax Rate % | -0.1% | 0% | 0% | 0% |
| Net Income | -597K▲ 0% | 4.46M▲ 847.7% | -12.54M▼ 380.8% | -31.74M▲ 0% |
| Net Margin % | - | - | - | -1635177.02% |
| Net Income Growth % | - | 847.74% | -380.85% | -6467.87% |
| Net Income (Continuing) | -597K | 4.46M | -12.54M | -31.74M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.07▲ 0% | 0.54▲ 845.9% | -1.52▼ 381.5% | -0.64▲ 0% |
| EPS Growth % | - | 845.86% | -381.48% | -1740.89% |
| EPS (Basic) | -0.07 | 0.54 | -1.52 | - |
| Diluted Shares Outstanding | 8.24M | 8.24M | 8.24M | 49.53M |
| Basic Shares Outstanding | 8.24M | 8.24M | 8.24M | 49.53M |
| Dividend Payout Ratio | - | - | - | - |
ASBPW Balance Sheet
Aspire Biopharma Holdings, Inc. (ASBPW) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Total Current Assets | 22.54K | 46.17K | 147.99K | 2.4M |
| Cash & Short-Term Investments | 38 | 11.17K | 3.63K | 1.95M |
| Cash Only | 38 | 11.17K | 3.63K | 1.95M |
| Short-Term Investments | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 36.5K | 0 |
| Days Sales Outstanding | - | - | - | 1.72K |
| Inventory | 0 | 0 | 0 | 35.44K |
| Days Inventory Outstanding | - | - | - | 3.06K |
| Other Current Assets | 0 | 0 | -36.5K | 0 |
| Total Non-Current Assets | 0 | 0 | 0 | 0 |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 299M | 19.9M | 6.67M | 6.67M |
| Other Non-Current Assets | -303.9M | -24.87M | -6.67M | -6.67M |
| Total Assets | 22.54K▲ 0% | 46.17K▲ 104.9% | 147.99K▲ 220.5% | 2.4M▲ 0% |
| Asset Turnover | - | - | - | 0.00x |
| Asset Growth % | - | 104.87% | 220.5% | 1345.82% |
| Total Current Liabilities | 151.33K | 534.03K | 1.69M | 13.86M |
| Accounts Payable | 122.73K | 172.77K | 310.22K | 1.06M |
| Days Payables Outstanding | - | - | - | 358.68K |
| Short-Term Debt | 27.97K | 360.64K | 1.27M | 8.62M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 626 | 626 | 111.03K | 3.91M |
| Current Ratio | 0.15x | 0.09x | 0.09x | 0.09x |
| Quick Ratio | 0.15x | 0.09x | 0.09x | 0.09x |
| Cash Conversion Cycle | - | - | - | -353.9K |
| Total Non-Current Liabilities | 0 | 0 | 0 | 9.9K |
| Long-Term Debt | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 108.49K |
| Total Liabilities | 151.33K | 534.03K | 1.69M | 13.87M |
| Total Debt | 27.97K | 360.64K | 1.27M | 8.62M |
| Net Debt | 27.93K | 349.46K | 1.26M | 6.68M |
| Debt / Equity | - | - | - | -0.75x |
| Debt / EBITDA | - | 0.08x | - | -0.31x |
| Net Debt / EBITDA | - | 0.08x | - | -0.24x |
| Interest Coverage | - | -149.47x | -3.46x | -10.51x |
| Total Equity | -128.79K▲ 0% | -487.86K▼ 278.8% | -1.54M▼ 215.7% | -11.47M▲ 0% |
| Equity Growth % | - | -278.8% | -215.68% | -3821.79% |
| Book Value per Share | -0.02 | -0.06 | -0.19 | -0.23 |
| Total Shareholders' Equity | -128.79K | -487.86K | -1.54M | -11.47M |
| Common Stock | 221.5K | 22K | 22K | 4.95K |
| Retained Earnings | -1.11M | -1.47M | -2.78M | -22.55M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
ASBPW Cash Flow Statement
Aspire Biopharma Holdings, Inc. (ASBPW) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|
| Cash from Operations | -142.91K | 11.14K | -265.19K | -265.19K |
| Operating CF Margin % | - | - | - | - |
| Operating CF Growth % | - | 107.79% | -2481.34% | -158.79% |
| Net Income | -597.12K | -359.07K | -1.31M | -31.74M |
| Depreciation & Amortization | 0 | 0 | 0 | 2.02M |
| Stock-Based Compensation | 0 | 0 | 0 | 14.13M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 0 | 0 | 0 | -1.43M |
| Working Capital Changes | 454.21K | 370.21K | 1.04M | 2.27M |
| Change in Receivables | 400K | 0 | 0 | -1.03M |
| Change in Inventory | 0 | 0 | 0 | -35.44K |
| Change in Payables | 102.73K | 50.04K | 0 | 1.12M |
| Cash from Investing | -4.9M | 284.92M | 13.78M | 0 |
| Capital Expenditures | -4.9M | -75.9K | 0 | 0 |
| CapEx % of Revenue | - | - | - | - |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 284.99M | 0 | 0 |
| Cash from Financing | 4.85M | -284.76M | 257.64K | 5.45M |
| Debt Issued (Net) | -252.91K | 0 | 1.71M | 4.56M |
| Equity Issued (Net) | 1000K | -1000K | 257.64K | 609.2K |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | -284.92M | 0 | 0 |
| Other Financing | 4.11M | 0 | -1.71M | 279.65K |
| Net Change in Cash | -185.46K▲ 0% | 11.14K▲ 106.0% | -7.54K▼ 167.7% | 1.93M▲ 0% |
| Free Cash Flow | -5.04M▲ 0% | -653.11K▲ 87.0% | -265.19K▲ 59.4% | -3.52M▲ 0% |
| FCF Margin % | - | - | - | -181147.76% |
| FCF Growth % | - | 87.04% | 59.4% | -223.61% |
| FCF per Share | -0.61 | -0.08 | -0.03 | -0.03 |
| FCF Conversion (FCF/Net Income) | 0.24x | 0.00x | 0.02x | 0.11x |
| Interest Paid | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 1.01K | 0 |
ASBPW Key Ratios
Aspire Biopharma Holdings, Inc. (ASBPW) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2023 | 2024 | TTM |
|---|---|---|---|
| Return on Equity (ROE) | - | - | 429.24% |
| Return on Invested Capital (ROIC) | - | - | 755.22% |
| Gross Margin | - | - | 45.54% |
| Net Margin | - | - | -1635177.02% |
| Debt / Equity | - | - | -0.75x |
| Interest Coverage | -149.47x | -3.46x | -10.51x |
| FCF Conversion | 0.00x | 0.02x | 0.11x |
ASBPW Frequently Asked Questions
Aspire Biopharma Holdings, Inc. (ASBPW) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Aspire Biopharma Holdings, Inc. (ASBPW) reported $0.0M in revenue for fiscal year 2024.
Aspire Biopharma Holdings, Inc. (ASBPW) grew revenue by 0.0% over the past year. Growth has been modest.
Aspire Biopharma Holdings, Inc. (ASBPW) reported a net loss of $31.7M for fiscal year 2024.
Dividend & Returns
Aspire Biopharma Holdings, Inc. (ASBPW) had negative free cash flow of $3.5M in fiscal year 2024, likely due to heavy capital investments.
Explore More ASBPW
Aspire Biopharma Holdings, Inc. (ASBPW) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates